U.S. FDA advisers back approval for Guardant's cancer test
23/05/2024 21:41
May 23 (Reuters) - Advisers to the U.S. Food and Drug
Administration on Thursday recommended for the approval of
Guardant Health's GH.O blood test to detect a cancer that
begins in the colon or rectum.
The panel voted seven-to-two in favor of benefits
outweighing risks when using the test called Shield for
colorectal cancer.
(Reporting by Puyaan Singh and Leroy Leo in Bengaluru; Editing
by Arun Koyyur)
((Puyaan.Singh@thomsonreuters.com;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns